Overview

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

Status:
Completed
Trial end date:
2018-01-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
Phase:
N/A
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
Brain & Behavior Research Foundation
Treatments:
Isradipine